Alumis's breakthrough trial results for its oral psoriasis drug have highlighted the massive potential of advanced autoimmune therapies. This theme focuses on the pharmaceutical companies pioneering next-generation oral treatments, particularly selective TYK2 inhibitors, which represent a new frontier in convenient and effective patient care.
Published on January 7
Recent Phase 3 trial results have validated a new class of oral treatments that could transform how autoimmune diseases are treated, moving away from inconvenient injections to simple pills.
These oral therapies could capture significant market share from the injectable biologics that currently dominate autoimmune treatment, representing a multi-billion pound opportunity.
Success in TYK2 inhibitor trials reduces development risk for other companies in this space, potentially accelerating approvals and driving sector-wide growth.
Recent breakthrough clinical trial results have validated selective TYK2 inhibitors as a promising new class of oral treatments for autoimmune diseases. This represents a potential shift away from injectable biologics that have dominated the market, offering patients more convenient treatment options with strong efficacy profiles.
This group focuses on pharmaceutical and biotechnology companies developing next-generation oral autoimmune therapies, particularly for psoriasis and related conditions. These companies range from established pharmaceutical giants to innovative clinical-stage biotechs, all working on treatments that could transform patient care in immunology.
Each company has been carefully selected for their involvement in TYK2 inhibitors, oral autoimmune treatments, or related therapeutic areas. The selection includes both companies with approved treatments and those with promising clinical pipelines, positioned to benefit from the growing validation of this therapeutic approach.
This basket's total market capitalisation is 1,994,443.68133, with its weight heavily concentrated in a limited number of large-cap stocks. That concentration tends to anchor performance, making the basket less sensitive to small-cap volatility.
BMY: $110.79B
PFE: $144.59B
AMGN: $177.79B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
+5
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+2.93%
On average, analysts expect assets in this group to grow 2.93% over the next year.
13 of 15 assets in this group are rated Buy by professional analysts.
